DK169609B1 - Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom - Google Patents

Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom Download PDF

Info

Publication number
DK169609B1
DK169609B1 DK275488A DK275488A DK169609B1 DK 169609 B1 DK169609 B1 DK 169609B1 DK 275488 A DK275488 A DK 275488A DK 275488 A DK275488 A DK 275488A DK 169609 B1 DK169609 B1 DK 169609B1
Authority
DK
Denmark
Prior art keywords
compound
disease
treatment
parkinson
hydrogen
Prior art date
Application number
DK275488A
Other languages
Danish (da)
English (en)
Other versions
DK275488A (da
DK275488D0 (da
Inventor
David Andrew Arlwydd Owen
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK169609(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of DK275488D0 publication Critical patent/DK275488D0/da
Publication of DK275488A publication Critical patent/DK275488A/da
Application granted granted Critical
Publication of DK169609B1 publication Critical patent/DK169609B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK275488A 1987-05-21 1988-05-19 Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom DK169609B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8712073 1987-05-21
GB878712073A GB8712073D0 (en) 1987-05-21 1987-05-21 Medicament

Publications (3)

Publication Number Publication Date
DK275488D0 DK275488D0 (da) 1988-05-19
DK275488A DK275488A (da) 1988-11-22
DK169609B1 true DK169609B1 (da) 1994-12-27

Family

ID=10617727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK275488A DK169609B1 (da) 1987-05-21 1988-05-19 Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom

Country Status (21)

Country Link
US (2) US4824860A (fr)
EP (1) EP0299602B1 (fr)
JP (1) JPH062672B2 (fr)
AT (1) ATE83659T1 (fr)
AU (1) AU599792B2 (fr)
CA (1) CA1305421C (fr)
DE (1) DE3876877T2 (fr)
DK (1) DK169609B1 (fr)
ES (1) ES2052717T3 (fr)
GB (1) GB8712073D0 (fr)
GR (1) GR3007251T3 (fr)
HK (1) HK1000913A1 (fr)
HU (1) HU201871B (fr)
IE (1) IE63511B1 (fr)
LU (1) LU90098I2 (fr)
MX (1) MX9203543A (fr)
NL (1) NL970006I2 (fr)
NZ (1) NZ224709A (fr)
PH (1) PH23867A (fr)
PT (1) PT87542B (fr)
ZA (1) ZA883602B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) * 1996-06-19 1996-08-21 Smithkline Beecham Plc Novel treatment
WO1998008819A1 (fr) * 1996-08-27 1998-03-05 American Home Products Corporation Derives de 4-aminoethoxy indolone
AU3555099A (en) * 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
ES2285245T3 (es) * 2002-09-13 2007-11-16 Motac Neuroscience Limited Tratamiento de la disquinesia con 2,3-benzodiazapinas.
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005051488A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Association d'agonistes de la dopamine et d'inhibiteurs de recaptage de la monoamine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20090325911A1 (en) * 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
CA2648479C (fr) 2006-04-06 2014-10-28 Nupathe Inc. Implants destines au traitement d'etats associes a la dopamine
WO2008001204A2 (fr) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (fr) * 2008-09-01 2010-03-04 Lupin Limited Nouvelles compositions de ropinirole à libération contrôlée
EP2346494A2 (fr) 2008-09-29 2011-07-27 Wockhardt Limited Forme posologique à libération prolongée de ropinirole
WO2010044108A2 (fr) 2008-10-17 2010-04-22 Rubicon Research Private Limited Formulations à libération contrôlée de ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
US20150313891A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones

Also Published As

Publication number Publication date
HU201871B (en) 1991-01-28
JPS63303966A (ja) 1988-12-12
DE3876877D1 (de) 1993-02-04
US4824860A (en) 1989-04-25
ZA883602B (en) 1989-04-26
CA1305421C (fr) 1992-07-21
IE63511B1 (en) 1995-05-03
EP0299602A3 (en) 1990-06-06
DK275488A (da) 1988-11-22
EP0299602B1 (fr) 1992-12-23
AU1644588A (en) 1988-11-24
NL970006I1 (nl) 1997-04-01
US4912126A (en) 1990-03-27
ES2052717T3 (es) 1994-07-16
AU599792B2 (en) 1990-07-26
ATE83659T1 (de) 1993-01-15
IE881469L (en) 1988-11-21
NL970006I2 (nl) 1997-10-01
GB8712073D0 (en) 1987-06-24
EP0299602A2 (fr) 1989-01-18
NZ224709A (en) 1997-02-24
GR3007251T3 (fr) 1993-07-30
JPH062672B2 (ja) 1994-01-12
DE3876877T2 (de) 1993-04-29
PT87542A (pt) 1989-05-31
MX9203543A (es) 1992-07-01
DK275488D0 (da) 1988-05-19
LU90098I2 (fr) 1997-09-25
HUT47217A (en) 1989-02-28
PH23867A (en) 1989-11-23
PT87542B (pt) 1992-09-30
HK1000913A1 (en) 1998-05-08

Similar Documents

Publication Publication Date Title
DK169609B1 (da) Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom
Devos et al. Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
CA2134038C (fr) Potentialisation des effets de medicaments
KR101760139B1 (ko) 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
Araki et al. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine
PT2083811T (pt) Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
EA015514B1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
KR20130101545A (ko) 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
CA2839350A1 (fr) Utilisation d'agonistes de recepteur de serotonine pour le traitement de troubles des mouvements
MXPA01009963A (es) Metodo para el tratamiento de padecimientos neurologicos o neuropsiquiatricos.
Korsgaard et al. The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist
KR20030053475A (ko) 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물
CN103889408A (zh) S1p受体调节剂或激动剂的剂量方案
Lees et al. Tiapride in levodopa-induced involuntary movements.
Pinder et al. Mianserin
WO2002067927A1 (fr) Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques
AU2002242296A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
Klawans Jr et al. Observations on the use of methysergide in Huntington's chorea
CN101584692A (zh) 左旋千金藤啶碱(l-SPD)衍生物的用途
Sandyk A drug naive parkinsonian patient successfully treated with weak electromagnetic fields
Weiner et al. Dopaminergic antagonism of L‐5‐hydroxytryptophan‐induced myoclonic jumping behavior
Liem‐Moolenaar et al. Early stage development of the glycine‐1 re‐uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
Wolters et al. Parkinson's disease.
EP1518554B1 (fr) Composition pharmaceutique pour le traitement de l'hyperhomocystéinémie

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1997 00011, 970131

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1997 00011, 970131, EXPIRES: 20110702

PUP Patent expired